As the life sciences sector pursues international expansion, it becomes increasingly vital to embed regulatory readiness into the core of strategic planning. At the 2026 J.P. Morgan Healthcare Conference, a panel moderated by Jodi Scott from Hogan Lovells brought together experts to discuss the evolving regulatory landscape impacting businesses in the U.S., China, and the EU. The panelists explored key themes such as artificial intelligence (AI) in healthcare, the influence of new legislation like the EU AI Act, and the challenges posed by tariffs and trade restrictions. They also projected significant regulatory changes anticipated in 2026, addressing the implications of emerging laws like the BIOSECURE Act and China’s Human Genetic Regulations (HGR).
Supply Chain Security and Regulatory Changes
The discussion commenced with Scott prompting her fellow panelists to identify crucial changes on the horizon. Joy Sturm, a partner in Hogan Lovells’ global regulatory practice, highlighted an intensified focus on supply chain security and the trend toward onshoring. She pointed out the BIOSECURE Act, aimed at limiting collaborations with biotechnology firms linked to foreign adversaries, as a significant development. Sturm underscored that tariffs will remain a pressing concern, particularly as the sector anticipates results from an ongoing Section 232 investigation into the biopharmaceutical industry. The emphasis on the “country of origin” for products is expected to draw heightened scrutiny from government agencies.
Accelerated Regulatory Reforms in China
Lu Zhou, from Hogan Lovells’ corporate and finance division, noted an unprecedented pace of regulatory reform in China. She emphasized the reduction in approval times for pharmaceuticals and medical devices, particularly for breakthrough therapies, which have been significantly expedited. The acceptance of real-world evidence (RWE) in regulatory applications indicates China’s desire to attract innovative companies to launch their products domestically or in tandem with international markets.
Zhou also pointed to China’s tightening of data security regulations, specifically through the implementation of the HGR. This legislation echoes the principles of the BIOSECURE Act, focusing on the management of Chinese genetic data. Additionally, she mentioned that China is positioning itself to be a leader in the AI space, encouraging localized research and manufacturing, particularly in special economic zones.
Convergence of Global Regulatory Expectations
Yarmela Pavlovic, Chief Regulatory Officer at Medtronic, added to the dialogue by discussing a growing convergence of regulatory expectations worldwide. She projected that global regulators will increasingly rely on cross-border collaboration, making it easier for companies to navigate international commercialization in 2026. However, she cautioned that the rapid evolution of technology could introduce both uncertainty and innovative regulatory policies.
Scott concurred, noting that as AI technology becomes more integrated into medical devices, companies will face new compliance challenges. The need for comprehensive documentation standards to meet global regulations will grow more pressing in the coming years.
Evolving Inspection Standards and Regulatory Compliance
Addressing the topic of inspections, Scott remarked that the FDA is enhancing its investigative capabilities through improved databases and AI tools. Meanwhile, Zhou noted that the National Medical Products Administration (NMPA) in China has increased lifecycle oversight of life sciences products, particularly focusing on data integrity issues.
Examining the timing of product approvals, Sturm indicated that while the potential to launch in China is becoming more attractive, it comes with growing concerns about data and trade restrictions. Zhou advised international companies operating in China to analyze and diversify their supply chains to mitigate risks associated with these complexities.
The Impact of New AI Regulations
As companies prepare for the new EU AI Act, Pavlovic explained that medical devices will face additional conformity assessments before entering the EU market. She pointed out that the industry is closely monitoring other countries, like South Korea, that are implementing similar regulatory frameworks. In the U.S., Scott noted that state-level regulations may emerge to address various aspects of AI, which could further complicate compliance for medical technology firms.
In contrast, Zhou described China’s approach to regulating AI-enabled medical devices as organized and centralized, with real-time data flow oversight by local government bodies. She cautioned that regulations in China can change rapidly, suggesting that companies establish SWOT teams to ensure proactive compliance.
Building Effective Communication Channels
Sturm emphasized the importance of establishing clear internal communication lines as regulations proliferate. She articulated that as regulatory frameworks expand, the development of robust internal systems for information flow becomes critical for success.
Pavlovic echoed this sentiment, reinforcing that effective internal communication is vital for medical device companies navigating complex regulatory landscapes.
Opportunities Amid Challenges
Pavlovic concluded the panel discussion by expressing optimism about the potential for global regulators to synchronize their medical product reviews through reliance frameworks. This trend could significantly reduce regulatory barriers, facilitating international expansion for companies in the life sciences sector.
The complexities of the global regulatory landscape present both challenges and opportunities. As the industry evolves, companies that adapt to these shifts while embracing innovation will be well-positioned for success.
Key Takeaways
- Regulatory readiness must be integrated into strategic planning for international expansion in life sciences.
- The BIOSECURE Act and China’s HGR are reshaping collaboration and compliance landscapes.
-
Accelerated regulatory reforms in China present both opportunities and challenges for global players.
-
Clear internal communication channels are essential for navigating regulatory complexities.
-
Global convergence of regulatory expectations can facilitate smoother international commercialization.
The dialogue at the J.P. Morgan Healthcare Conference underscores the importance of staying informed and agile in an ever-shifting regulatory environment. Companies that harness these insights will not only navigate challenges but also seize opportunities in the global market.
Read more → www.jdsupra.com